T
MREO

Transce3nd’s Mereo BioPharma MREO Stock Holding History

Transce3nd’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-127
Closed -$344 – 768
2025
Q2 		$344 Hold
127
– – ﹤0.01% 1133
2025
Q1 		$286 Hold
127
– – ﹤0.01% 1100
2024
Q4 		$445 Buy
+127
New +$499 ﹤0.01% 1316

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Transce3nd's MREO Position: Q3 2025 in Review

Transce3nd sold out of Mereo BioPharma (MREO) in Q3 2025, closing a stake of 127 shares — an estimated $344 sold.

Transce3nd first reported a position in MREO in Q4 2024 and held it in 3 quarters. The position peaked at $445 in Q4 2024. 84 funds tracked by Wall St. Rank hold MREO as of Q3 2025.

  • Transce3nd reported no remaining Mereo BioPharma position as of Q3 2025 after selling out during the quarter.
  • Transce3nd sold 127 Mereo BioPharma shares in Q3 2025, an estimated $344.
  • Transce3nd first reported a position in Mereo BioPharma in Q4 2024 and held it in 3 quarters.
  • Transce3nd's Mereo BioPharma position peaked at $445 in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.